Vivus Evamist Menopause Spray To Start Phase III Under Special Protocol Assessment

Firm will conduct single 12-week trial for treatment of moderate to severe vasomotor symptoms with the transdermal estradiol spray. Evamist would be the first estradiol topical spray formulation, Vivus says.